Low specificity of HLA-DR expression for diagnosis of acute promyelocytic leukemia
- Authors: Mikhailova E.V.1, Mochalova N.S.1, Kashpor S.A.1, Zerkalenkova E.A.1, Konyukhova T.V.1, Plyasunova S.A.1, Olshanskaya Y.V.1, Kalinina I.I.1, Maschan M.A.1, Maschan A.A.1, Novichkova G.A.1, Popov A.M.1
-
Affiliations:
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
- Issue: Vol 21, No 1 (2022)
- Pages: 42-48
- Section: ORIGINAL ARTICLES
- Submitted: 27.03.2022
- Accepted: 27.03.2022
- Published: 27.03.2022
- URL: https://hemoncim.com/jour/article/view/588
- DOI: https://doi.org/10.24287/1726-1708-2022-21-1-42-48
- ID: 588
Cite item
Full Text
Abstract
Contemporary therapy of acute promyelocytic leukemia (APL) is based on the use of all-trans retinoic acid, which is effective against tumor cells harboring RARa gene rearrangements (most common – t(15;17)(q24;q21)/PML::RARa). In several studies, it was suggested to use typical immunophenotypic features of APL (HLA-DR-negativity, etc) for prediction of RARa rearrangements presence. In this study, we aimed to evaluate the range of genetic aberrations that could be found in the HLA-DR-negative acute myeloid leukemia (AML). Our study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Among studied 806 pediatric AML patients, HLA-DR-negativity was found in 253 cases. Only in 45.4% of them t(15;17)(q24;q21)/PML::RARa was found, while in remaining 54.6% normal karyotype or other genetic aberrations without RARa involvement. Frequency of the most common immunophenotypic features of APL, such as total CD117, CD33 and MPO expression with the lack of CD34, was higher in patients with t(15;17)(q24;q21)/PML::RARa, although only two thirds of APL cases were found to have all these signs. Moreover, the percentage of cells positive or negative for mentioned antigens varied significantly in APL group. Thus we can conclude, that all “typical” immunophenotypic characteristics of APL including HLA-DR-negativity, are very unspecific and cannot be used for reliable prediction of presence of t(15;17)(q24;q21)/PML::RARa.
About the authors
E. V. Mikhailova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
Author for correspondence.
Email: katmikhailova1805@gmail.com
ORCID iD: 0000-0002-3450-0498
Ekaterina V. Mikhailova, MD, Leukemia Immunophenotyping Laboratory
1 Samory Mashela St., 117997, Moscow
Russian FederationN. S. Mochalova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-9473-6398
Moscow
Russian FederationS. A. Kashpor
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-5220-7412
Moscow
Russian FederationE. A. Zerkalenkova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0001-9634-5828
Moscow
Russian FederationT. V. Konyukhova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0001-6271-7435
Moscow
Russian FederationS. A. Plyasunova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-4503-0735
Moscow
Russian FederationYu. V. Olshanskaya
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-2352-7716
Moscow
Russian FederationI. I. Kalinina
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-0813-5626
Moscow
Russian FederationM. A. Maschan
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0003-1735-0093
Moscow
Russian FederationA. A. Maschan
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-0016-6698
Moscow
Russian FederationG. A. Novichkova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-2322-5734
Moscow
Russian FederationA. M. Popov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-0889-6986
Moscow
Russian FederationReferences
Supplementary files
